Levels of VEGF but not VEGF165b are Increased in the Vitreous of Patients With Retinal Vein Occlusion

Ehlken, Christoph; Rennel, Emma; Michels, Daniel de Sousa; Grundel, Bastian; Pielen, Amelie; Junker, Bernd; Stahl, Andreas; Hansen, Lutz L.; Feltgen, Nicolas; Agostini, Hansjürgen; Martin, Gottfried

doi:10.1016/j.ajo.2011.01.040

Cited by 51 publications

(35 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The average vitreal concentration of VEGF in CRVO is 8.6 ng/ ml in CRVO and 2.0 ng/ml in BRVO as compared to 0.26 ng/ml in normal eyes [26].A lower concentration of intraocular VEGF is required to increase vascular permeability than that required to induce neovascularisation.…”

Section: Complicationmentioning

confidence: 95%

Effect of Posterior Sub–Tenon Triamcinolone in Macular Edema Due to Non–Ischemic Vein Occlusions

Gurram

2013

JCDR

View full text Add to dashboard Cite

Purpose: To study the efficacy and safety of Posterior SubTenon Triamcinolone acetonide (PSTT) in the treatment of macular edema in retinal vein occlusions. The efficacy is studied by anatomical and visual improvements. Methods: This study was a prospective interventional case series. 24 eyes of 24 patients (13 male and 11 female) with recent onset non-ischemic RVO (Retinal Vein Occlusion) underwent Posterior Sub-Tenon Triamcinolone (PSTT). Of the 24 eyes treated, 18 eyes were of BRVO (Branch Retinal Vein Occlusion) and 6 were CRVO (Central Retinal Vein Occlusion). All the eyes received 40 mg of Triamcinolone Acetonide (TA) in 1ml through posterior sub-tenon route. All the eyes were examined at baseline and after four weeks of being injected with TA. Changes in the best corrected visual acuity {letters of ETDRS (Early Treatment Diabetic Retinopathy Study) chart} and Central Macular Thickness (CMT) were studied. A gain of more than 5 letters was considered as effective. The eyes were examined for raised IOP (Intra-Ocular Pressure) and other complications.Results: Out of the 24 eyes 19 (79%) showed an improvement of more than 5 letters after a month of treatment. All the patients exhibited a certain degree of decrease in CMT. The mean BCVA increased from 30.08±10.16 to 40.21±8.93 (p<0.05). The mean CMT decreased from 575.08±131.55 to 282.08±163.99 (p<0.05).

show abstract

Section: Complicationmentioning

confidence: 95%

Effect of Posterior Sub–Tenon Triamcinolone in Macular Edema Due to Non–Ischemic Vein Occlusions

Gurram

2013

JCDR

View full text Add to dashboard Cite

show abstract

“…In RVO patients, the VEGF concentration in the ocular fluid is increased, which correlates with the severity of macular edema [5,[18][19][20]. Several anti-VEGF agents have been widely used for treating macular edema secondary to RVO, including ranibizumab.…”

Section: Introductionmentioning

confidence: 99%

Real-Life Clinical Effectiveness of Razumab® (the World’s First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study

Sharma¹,

Khan²,

Chaturvedi³

2018

Ophthalmologica

View full text Add to dashboard Cite

Background: This subgroup analysis of the RE-ENACT study evaluates the effectiveness of Razumab® (the world’s first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) in Indian patients with retinal vein occlusion (RVO). Methods: The data on patients with RVO who had received ≥3 injections of Razumab® between January and August 2016 were analyzed. Endpoints were: improvement in best corrected visual acuity (BCVA), and a decrease in central macular thickness (CMT), intraretinal fluid (IRF), and subretinal fluid (SRF) from baseline at weeks 4, 8, and 12. Results: Of 160 patients, the majority (61.87%) were men. The mean (±SE) BCVA improved from baseline (0.76 ± 0.04) to week 4 (0.73 ± 0.03; p = 0.0656), which attained significance at week 8 (0.55 ± 0.02; p < 0.0001) and week 12 (0.47 ± 0.02; p < 0.0001). The mean (±SE) CMT significantly decreased from baseline (447.60 ± 10.91 μm) to week 4 (431.84 ± 10.92 μm; p = 0.0028), week 8 (339.28 ± 8.12 μm; p < 0.0001), and week 12 (298.23 ± 6.68 μm; p < 0.0001). The proportion of patients with IRF and SRF significantly (p < 0.0001) decreased from baseline to weeks 4, 8, and 12 (IRF: from 70.63 to 45.63, 39.38, and 30.00%, respectively; SRF: from 65.63 to 37.50, 28.13, and 24.38%, respectively). A subgroup analysis of branch RVO and central RVO showed similar results. No new safety concerns were observed. Conclusion: Razumab® (biosimilar of ranibizumab) effectively improved visual acuity and disease outcomes in patients with RVO in a real-world setting with no new safety concerns.

show abstract

“…The role of VEGF in the pathogenesis of macular edema secondary to CRVO has been postulated on the basis of raised protein levels in vitreous gel samples of eyes with CRVO [15]. Early treatment strategies used bevacizumab to reduce the amount of VEGF in venous occlusive disease [9,11,16].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

Kreutzer

Wolf²,

Dirisamer³

et al. 2014

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Purpose: This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Methods: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. Results: At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Conclusion: Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI.

show abstract

Levels of VEGF but not VEGF165b are Increased in the Vitreous of Patients With Retinal Vein Occlusion

Cited by 51 publications

References 40 publications

Effect of Posterior Sub–Tenon Triamcinolone in Macular Edema Due to Non–Ischemic Vein Occlusions

Effect of Posterior Sub–Tenon Triamcinolone in Macular Edema Due to Non–Ischemic Vein Occlusions

Real-Life Clinical Effectiveness of Razumab® (the World’s First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study

Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

Contact Info

Product

Resources

About